PG 201

Drug Profile

PG 201

Alternative Names: Layla; PG201

Latest Information Update: 08 May 2014

Price : $50

At a glance

  • Originator ViroMed Co Ltd
  • Developer PMG Pharm Co Ltd
  • Class Antirheumatics; Phytotherapies
  • Mechanism of Action Cytokine modulators; Interleukin 1 beta inhibitors; Matrix metalloproteinase inhibitors; Tumour necrosis factor alpha modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Osteoarthritis

Most Recent Events

  • 08 May 2014 PMG initiates enrolment in a phase IV LAYLA_P4_NB trial for Osteoarthritis in South Korea (NCT02049606)
  • 01 Sep 2013 PMG Pharm completes a phase IV LAYLA-P4 trial in Osteoarthritis (NCT01768468)
  • 01 Dec 2012 Launched for Osteoarthritis in South Korea (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top